MDxHealth Signs Agreement With Stratose(R) to Expand Insurance Coverage for ConfirmMDxTM for Prostate Cancer Test

MDxHealth Signs Agreement With Stratose(R) to Expand Insurance Coverage for 
ConfirmMDxTM for Prostate Cancer Test 
IRVINE, CA, and HERSTAL, BELGIUM -- (Marketwired) -- 09/03/13 -- 
MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular
diagnostic company that develops and commercializes epigenetic tests
to support the diagnosis and treatment of cancer patients, today
announced that it has entered into an agreement with Stratose, one of
the largest healthcare PPO network providers in the U.S. The
agreement provides Stratose's 12.4 million member network with access
to ConfirmMDx for Prostate Cancer testing.  
ConfirmMDx for Prostate Cancer provides urologists and their patients
with a non-invasive approach to address false-negative biopsy
concerns. The test provides urologists with actionable information on
the decision for repeat biopsy, aiding in the stratification of
patients at sufficiently low risk who may avoid repeat biopsy and
return to screening, from those who may be at increased risk for
harboring undetected cancer, meriting repeat biopsy and potentially
treatment.  
"MDxHealth continues to work with payers and specialty networks to
expand patient and customer access to the ConfirmMDx for Prostate
Cancer test. Stratose's network supplements more than 90 different
third-party insurance payers. Since 70% of all MDxHealth ConfirmMDx
cases are billed to commercial and third-party payers, these
contracts are very important," said Dr. Jan Groen, CEO of MDxHealth.
"With the addition of Stratose to our existing payer agreements, more
than 80 million covered lives now have access to ConfirmMDx for
Prostate Cancer." 
Stratose (formerly operating as Coalition America, NPPN, OPPN,
PlanCare America, 4MOST Health, Qualident and KeyClaims) works to
reduce the cost and ensure the best financial results on every
medical, dental and workers' compensation claim for any claims payer.
The company maintains one of the largest directly managed PPO
networks in the U.S., including more than 850,000 direct and
affiliate medical, dental and workers' compensation provider
contracts.  
About MDxHealth(R) 
 MDxHealth is a molecular diagnostics company
that develops and commercializes advanced epigenetic tests for cancer
assessment and the personalized treatment of patients. The company's
first commercial product, ConfirmMDx(TM) for Prostate Cancer, has
been shown to help distinguish patients who have a true-negative
biopsy from those who may have undetected cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer
diagnosis and treatment information. The company has a proprietary
platform and a strong epigenetic product pipeline focused on the
development of products for prostate, brain and lung cancers. The
company is based in Irvine, California with a European headquarters
in Herstal, Belgium. For more information visit MDxHealth's website
at www.mdxhealth.com. 
This press release contains forward-looking statements and estimates
with respect to the anticipated future performance of MDxHealth and
the market in which it operates. Such statements and estimates are
based on assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable but may
not prove to be correct. Actual events are difficult to predict, may
depend upon factors that are beyond the company's control, and may
turn out to be materially different. MDxHealth expressly disclaims
any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statement is based unless required by law or regulation. This
press release does not constitute an offer or invitation for the sale
or purchase of securities or assets of MDxHealth in any jurisdiction.
No securities of MDxHealth may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933, as
amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. securities laws. 
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are
trademarks or registered trademarks of MDxHealth SA. All other
trademarks and service marks are the property of their respective
owners. 
To access the PDF version, please click here :
http://hugin.info/137314/R/1726660/576219.pdf  
For more information:  
Dr. Jan Groen
CEO 
MDxHealth
US: +1 949 812 6979
BE: +32 43642070 
info@mdxhealth.com  
Mike Sinclair 
Halsin Partners
UK: +44 20 7318 2955 
Cell:+44 7968 022075 
msinclair@halsin.com  
Matt Clawson
Allen & Caron, Inc
US: +1 949 474 4300
matt@allencaron.com 
 
 
Press spacebar to pause and continue. Press esc to stop.